drugset / Trial / NCT00414089

Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL

NCT00414089

Phase 2 Withdrawn AHS Cancer Control Alberta
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see how well Zevalin works in the treatment of low grade indolent B-cell lymphoma when given to patients who have not had any previous treatment for their lymphoma and who otherwise would be followed on a "watch \& wait" policy.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject 90Y-ibritumomab tiuxetan Other / unclassified

Indications